TB-500 (thymosin β-4 fragment)
Research-use contextResearch-use peptide · also: tb500, tb 500, thymosin beta-4 fragment, thymosin beta 4
A synthetic fragment related to thymosin β-4, sold as a research-use product; not FDA-approved.
People commonly track it for
Most often logged in a soft-tissue recovery context — again, user intent, not a proven effect.
Evidence summary
Published human studies generally used full-length thymosin β-4; human data on the shorter TB-500 fragment specifically is very limited (the first registered fragment trial only began recruiting in 2026).
Regulation & source status
Not FDA-approved. Among the peptides under FDA compounding review as of July 2026 — under review is not approval.
Route considerations
Commonly discussed as an injectable in community settings. We don't provide route, preparation, or technique guidance — that's a clinician/pharmacist conversation.
Storage considerations
Often sold as a powder for reconstitution; unregulated products have no verified storage or stability data. Storage specifics belong to a pharmacist, not this profile.
Interaction & context review
Because human data is limited, interactions aren't well characterized. If you track it alongside other items or medications, review the full list with a clinician or pharmacist.
Sport / duty status
Prohibited in sport — WADA S2 covers thymosin-β4 and its derivatives such as TB-500.
Track this item
You can log this as a custom peptide / medication-context item — record your own source status, route, storage note, and a schedule, and include it in an export for your clinician. StackWise doesn't add a dose.
Track this itemPeptide safety & source review
Sources
- FDA — PCAC meeting, July 23–24, 2026 (503A bulks review)
- WADA — Prohibited List
- ClinicalTrials.gov — thymosin β-4 (full-length) human study
Source reviewed: 2026-07-23.